Hair-loss treatment stocks emerge as Korea's latest market theme
Hair-loss treatment stocks have emerged as the latest theme in Korea's equity market, drawing investors searching for the next big pharmaceutical trade after the boom in obesity drugs, market watchers said Monday. Shares of JW Shinyak and Samik Pharm jumped 55.48 percent and 22.91 percent over the past week, respectively, as enthusiasm spread across Korean companies seen as having exposure to the…
Hair-loss treatment stocks have become the latest trend in South Korea's stock market, according to market analysts. Investors are looking for the next major pharmaceutical opportunity following the recent success of obesity drugs, according to industry observers. Shares in JW Shinyak and Samik Pharm skyrocketed 55.48% and 22.91% respectively over the past week as interest in the hair-loss sector spread among Korean firms with potential exposure to this market. Hyundai Pharmaceutical also experienced a 29.06% increase.
JW Shinyak, a pharmaceutical subsidiary of JW Group, sells prescription medications through hospitals, clinics, and pharmacies. Their portfolio includes both oral and topical solutions for hair loss, and they are currently venturing into the hair care cosmetics industry. Hyundai Pharmaceutical has a long history in Korea's hair-loss drug market, with a presence dating back 39 years.
Samik Pharm is aiming to become the next generation in this space. In January, they secured a patent for a platform technology designed to transform daily oral hair-loss drugs into monthly long-acting injections. These gains were not limited to pharmaceutical companies. Bioneer, a developer of hair-loss treatments, is also gaining attention.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- Frieze, Kiaf Seoul point to Korea's recovering art market koreatimes.co.kr
